11:08 AM EDT, 06/10/2025 (MT Newswires) -- Gilead Sciences ( GILD ) said Tuesday that the US Food and Drug Administration has paused the company's HIV treatment trials involving two experimental drugs, GS-1720 and GS-4182.

The pause was made after a safety signal was triggered as some participants who received both drugs showed drops in CD4+T-cell and lymphocyte counts, the company said.

Gilead said three additional phase 1 trials of either agent and/or their combinations are also on hold.

Shares of Gilead Sciences ( GILD ) were down about 2% in recent trading.

Price: 110.96, Change: -2.04, Percent Change: -1.81